1
项与 Anti-CD19/CD22 CAR-T cell therapy(Shenzhen BindeBIo) 相关的临床试验A Clinical Study Evaluating the Safety and Efficacy of CAR-T19/CAR-T22 Treatment for Children With CD19 Positive Relapse or Refractory Childhood Acute Lymphoblastic Leukemia and Lymphoma
This is a single arm, open-label, uni-center, phase I study . In this study, Children withCD19+/CD22+ R/R B-cell acute lymphoblastic leukemia or lymphoma will be treated with CAR-T19/CAR-T22 Immunotherapy to determine the safety and efficacy of treatment.
100 项与 Anti-CD19/CD22 CAR-T cell therapy(Shenzhen BindeBIo) 相关的临床结果
100 项与 Anti-CD19/CD22 CAR-T cell therapy(Shenzhen BindeBIo) 相关的转化医学
100 项与 Anti-CD19/CD22 CAR-T cell therapy(Shenzhen BindeBIo) 相关的专利(医药)
100 项与 Anti-CD19/CD22 CAR-T cell therapy(Shenzhen BindeBIo) 相关的药物交易